The systemic administration of the αEGFR-172 (200 μg each time, intraperitoneal injection three times) can be well tolerated and achieve tumor remission in 60% of mice bearing B16-F10 tumors, while anti-PD-L1 antibody (200 μg) only modestly reduced tumor growth. Here, CD274 is linked to neoplasm.